Up 68% from Its IPO, Is Doximity Still Worth Buying?

In the business world, there's Microsoft's (NASDAQ: MSFT) LinkedIn, and in the medical world, there's Doximity (NYSE: DOCS). The company's platform has not only allowed doctors across America to effectively grow their careers, but it has also enabled easier communication and modernized how doctors receive news about emerging treatments. 

Doximity makes communication between doctors easier than ever before, but there are questions about how much longer this business could grow. Doximity is already up 68%, and with its seemingly limited growth strategy, there might not be much room for investors to make money on this investment.

Image source: Getty Images.

Continue reading

Source Fool.com